Serum Institute of India Invests in IntegriMedical
Serum Institute of India (SII) has announced a strategic investment in IntegriMedical, acquiring a 20% stake in the company, to advance Needle-Free Injection System technology. The partnership between SII and IntegriMedical aligns with SII's vision of 'Health for All' and IntegriMedical's mission to ‘Transform Healthcare Globally’ by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion. IntegriMedical has developed a US patented Needle-Free Injection System (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs. The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a pleasant and stress-free experience. Read more@ https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/pharma-fi